{"id":505,"date":"2026-08-28T06:10:55","date_gmt":"2026-08-28T04:10:55","guid":{"rendered":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/"},"modified":"2026-08-28T06:11:16","modified_gmt":"2026-08-28T04:11:16","slug":"prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy","status":"publish","type":"post","link":"https:\/\/www.pqra.gr\/el\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/","title":{"rendered":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy"},"content":{"rendered":"<p style=\"font-size:19px;line-height:1.7;color:#33414d;\"><strong>The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment at review, and conditional marketing authorisation at approval. They are frequently confused, and they are frequently used in the wrong order. Each has its own entry point, its own evidentiary bar and its own long tail of obligations. Companies that treat them as a single &ldquo;fast track&rdquo; tend to arrive at the CHMP with a dossier that does not support any of them.<\/strong><\/p>\n<h2>PRIME: support during development, not a designation<\/h2>\n<p>PRIME (PRIority MEdicines) has run since March 2016. It is not an approval pathway &mdash; it is an enhanced-support scheme for medicines targeting conditions with no satisfactory treatment option, or where the product offers a major therapeutic advantage. Entry is open to sponsors in the exploratory clinical trial phase, on the strength of preliminary clinical evidence of promising activity. It is expressly <em>\u03b4\u03b5\u03bd<\/em> intended for products already in advanced development, in the pre-submission phase, or authorised in the EU with a new indication in view.<\/p>\n<p>Once eligibility is granted, the support package is concrete:<\/p>\n<ul>\n<li>A PRIME Scientific Coordinator appointed immediately as a dedicated EMA contact point<\/li>\n<li>Early appointment of a CHMP or CAT rapporteur, one month after eligibility<\/li>\n<li>A multidisciplinary kick-off meeting three to four months in<\/li>\n<li>Iterative scientific advice, with the option to involve HTA bodies, patients and the US FDA<\/li>\n<li>A submission readiness meeting roughly a year before the marketing authorisation application<\/li>\n<li>Confirmation of potential accelerated assessment at the time of application<\/li>\n<\/ul>\n<p>Three features piloted between 2023 and 2025 &mdash; expedited scientific advice, the submission readiness meeting, and a regulatory roadmap and product development tracker &mdash; are now standard parts of the scheme; EMA published its pilot report in March 2026. SMEs and academic sponsors can enter earlier still, under Early Entry PRIME, on proof of principle. All requests are submitted through the IRIS platform.<\/p>\n<h2>Accelerated assessment: a shorter clock, requested late<\/h2>\n<p>Accelerated assessment is a separate request, made under Article 14(9) of Regulation (EC) No 726\/2004. It compresses the CHMP review from up to 210 days to 150 days, excluding clock stops. The request should be made at least two to three months before the application is submitted, and EMA strongly recommends a pre-submission meeting six to seven months out.<\/p>\n<p>PRIME participation does not confer it automatically. The applicant must still justify that the product is of major public health interest, particularly from the standpoint of therapeutic innovation &mdash; and a compressed clock leaves far less room to answer a major objection. Any GMP or GCP inspection needs must be flagged early so that inspections can be built into the timetable rather than derailing it.<\/p>\n<h2>Conditional marketing authorisation: approval with a debt attached<\/h2>\n<p>Conditional marketing authorisation (CMA), governed by Article 14-a of Regulation (EC) No 726\/2004 and Regulation (EC) No 507\/2006, allows approval on less comprehensive clinical data. Four criteria must all be met: a positive benefit-risk balance; a realistic prospect of providing comprehensive data post-authorisation; an unmet medical need; and a benefit of immediate availability that outweighs the risk of the outstanding data.<\/p>\n<p>A CMA is valid for one year and renewable annually. The holder must apply for renewal at least six months before expiry, with an interim report on the specific obligations. Those obligations &mdash; completing ongoing studies, running new ones, collecting confirmatory data &mdash; are listed in the authorisation and published in the EPAR. PSURs are due at least every six months. Once the obligations are discharged and the full data confirm the benefit-risk balance, the authorisation converts to a standard one, initially valid for five years.<\/p>\n<p>CMA should not be confused with authorisation under exceptional circumstances, which applies where comprehensive data can never realistically be generated and which does not normally lead to a standard authorisation. Applicants intending to request a CMA should flag it in the notification of intention to submit, six to seven months ahead of the application, and again formally within the application itself.<\/p>\n<h2>Sequencing the three<\/h2>\n<p>The practical failure mode is treating early access as a filing decision rather than a development decision. PRIME is chosen in early clinical development; accelerated assessment is requested months before filing; the CMA request is embedded in the dossier. Each one raises the evidentiary expectations for the next, and a CMA in particular carries a confirmatory programme that must be funded, staffed and pharmacovigilance-supported for years. Market access adds a further layer: HTA bodies and national payers apply their own standards to immature data, and in Greece that conversation runs on its own timetable.<\/p>\n<h2>How PQRA helps<\/h2>\n<p>PQRA advises pharmaceutical companies and healthcare innovators on early access strategy across the EU and Greece &mdash; assessing whether a product realistically meets the PRIME and CMA criteria, preparing eligibility justifications and pre-submission requests, structuring dossiers that support a compressed review, and building the pharmacovigilance and confirmatory-evidence infrastructure that post-approval obligations demand. We align the regulatory route with the reimbursement route from the outset, so that early approval does not become delayed access.<\/p>\n<p><a href=\"\/el\/contact\/\">Contact PQRA<\/a> to discuss an early access strategy for your product.<\/p>","protected":false},"excerpt":{"rendered":"<p>The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment at review, and conditional marketing authorisation at approval. They are frequently confused, and they are frequently used in the wrong order. Each has its own entry point, its own evidentiary [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":506,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"saved_in_kubio":false,"_swpsp_post_exclude":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pqra.gr\/el\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"el_GR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA\" \/>\n<meta property=\"og:description\" content=\"The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment at review, and conditional marketing authorisation at approval. They are frequently confused, and they are frequently used in the wrong order. Each has its own entry point, its own evidentiary [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pqra.gr\/el\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"PQRA\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T04:10:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T04:11:16+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 \u03bb\u03b5\u03c0\u03c4\u03ac\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\"},\"headline\":\"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy\",\"datePublished\":\"2026-08-28T04:10:55+00:00\",\"dateModified\":\"2026-08-28T04:11:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/\"},\"wordCount\":856,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/prime-accelerated-conditional-early-access.png\",\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/\",\"name\":\"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/prime-accelerated-conditional-early-access.png\",\"datePublished\":\"2026-08-28T04:10:55+00:00\",\"dateModified\":\"2026-08-28T04:11:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#breadcrumb\"},\"inLanguage\":\"el\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/prime-accelerated-conditional-early-access.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/prime-accelerated-conditional-early-access.png\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pqra.gr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#website\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"name\":\"PQRA\",\"description\":\"Your trusted partner in Pharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pqra.gr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"el\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#organization\",\"name\":\"PQRA\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"contentUrl\":\"https:\\\/\\\/www.pqra.gr\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/pqra-logo-white.png\",\"width\":594,\"height\":362,\"caption\":\"PQRA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pqra.gr\\\/#\\\/schema\\\/person\\\/31e1a03125e7281efaddd7278681af2c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"el\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"https:\\\/\\\/www.pqra.gr\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pqra.gr\/el\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/","og_locale":"el_GR","og_type":"article","og_title":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA","og_description":"The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment at review, and conditional marketing authorisation at approval. They are frequently confused, and they are frequently used in the wrong order. Each has its own entry point, its own evidentiary [&hellip;]","og_url":"https:\/\/www.pqra.gr\/el\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/","og_site_name":"PQRA","article_published_time":"2026-08-28T04:10:55+00:00","article_modified_time":"2026-08-28T04:11:16+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u03a3\u03c5\u03bd\u03c4\u03ac\u03c7\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc":"admin","\u0395\u03ba\u03c4\u03b9\u03bc\u03ce\u03bc\u03b5\u03bd\u03bf\u03c2 \u03c7\u03c1\u03cc\u03bd\u03bf\u03c2 \u03b1\u03bd\u03ac\u03b3\u03bd\u03c9\u03c3\u03b7\u03c2":"4 \u03bb\u03b5\u03c0\u03c4\u03ac"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#article","isPartOf":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/"},"author":{"name":"admin","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c"},"headline":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy","datePublished":"2026-08-28T04:10:55+00:00","dateModified":"2026-08-28T04:11:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/"},"wordCount":856,"commentCount":0,"publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"image":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/08\/prime-accelerated-conditional-early-access.png","articleSection":["Uncategorized"],"inLanguage":"el","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/","url":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/","name":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy - PQRA","isPartOf":{"@id":"https:\/\/www.pqra.gr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/08\/prime-accelerated-conditional-early-access.png","datePublished":"2026-08-28T04:10:55+00:00","dateModified":"2026-08-28T04:11:16+00:00","breadcrumb":{"@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#breadcrumb"},"inLanguage":"el","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#primaryimage","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/08\/prime-accelerated-conditional-early-access.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/08\/prime-accelerated-conditional-early-access.png","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.pqra.gr\/prime-accelerated-assessment-and-conditional-approval-building-an-early-access-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pqra.gr\/"},{"@type":"ListItem","position":2,"name":"PRIME, Accelerated Assessment and Conditional Approval: Building an Early Access Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.pqra.gr\/#website","url":"https:\/\/www.pqra.gr\/","name":"PQRA","description":"Your trusted partner in Pharma","publisher":{"@id":"https:\/\/www.pqra.gr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pqra.gr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"el"},{"@type":"Organization","@id":"https:\/\/www.pqra.gr\/#organization","name":"PQRA","url":"https:\/\/www.pqra.gr\/","logo":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/","url":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","contentUrl":"https:\/\/www.pqra.gr\/wp-content\/uploads\/2026\/07\/pqra-logo-white.png","width":594,"height":362,"caption":"PQRA"},"image":{"@id":"https:\/\/www.pqra.gr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.pqra.gr\/#\/schema\/person\/31e1a03125e7281efaddd7278681af2c","name":"admin","image":{"@type":"ImageObject","inLanguage":"el","@id":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/656b750ec6bc02db9de84dc3080e82be722c7777ef23ff04d6e8e7a0ac541a45?s=96&d=mm&r=g","caption":"admin"},"sameAs":["https:\/\/www.pqra.gr"]}]}},"_links":{"self":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/comments?post=505"}],"version-history":[{"count":1,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/505\/revisions"}],"predecessor-version":[{"id":507,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/posts\/505\/revisions\/507"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media\/506"}],"wp:attachment":[{"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/media?parent=505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/categories?post=505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pqra.gr\/el\/wp-json\/wp\/v2\/tags?post=505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}